Xanax ® — Net Sales
Viatris Xanax ® — Net Sales decreased by 11.9% to $34.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.7%, from $32.30M to $34.80M. Over 4 years (FY 2021 to FY 2025), Xanax ® — Net Sales shows a downward trend with a -6.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests strong brand loyalty or effective market penetration, while a decrease may indicate increased generic competition, patent expirations, or shifts in prescribing patterns.
Detailed definition
This metric represents the total revenue generated from the sale of the Xanax brand product line after accounting for re...
Peer comparison
Comparable to revenue metrics for mature, off-patent pharmaceutical brands at other large-cap generic and specialty drug manufacturers.
vtrs_segment_xanax_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $48.80M | $47.60M | $44.40M | $40.00M | $37.20M | $38.30M | $41.00M | $39.70M | $51.80M | $28.20M | $35.10M | $34.50M | $35.40M | $38.60M | $36.50M | $32.30M | $33.90M | $34.20M | $39.50M | $34.80M |
| QoQ Change | — | -2.5% | -6.7% | -9.9% | -7.0% | +3.0% | +7.0% | -3.2% | +30.5% | -45.6% | +24.5% | -1.7% | +2.6% | +9.0% | -5.4% | -11.5% | +5.0% | +0.9% | +15.5% | -11.9% |
| YoY Change | — | — | — | — | -23.8% | -19.5% | -7.7% | -0.8% | +39.2% | -26.4% | -14.4% | -13.1% | -31.7% | +36.9% | +4.0% | -6.4% | -4.2% | -11.4% | +8.2% | +7.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's xanax ® — net sales?
- Viatris (VTRS) reported xanax ® — net sales of $34.80M in Q1 2026.
- How has Viatris's xanax ® — net sales changed year-over-year?
- Viatris's xanax ® — net sales increased by 7.7% year-over-year, from $32.30M to $34.80M.
- What is the long-term trend for Viatris's xanax ® — net sales?
- Over 4 years (2021 to 2025), Viatris's xanax ® — net sales has grown at a -6.9% compound annual growth rate (CAGR), from $185.90M to $139.90M.
- What does xanax ® — net sales mean?
- The total revenue earned from sales of the Xanax brand product line.